Ronald C. Keating - 24 May 2023 Form 4 Insider Report for Evoqua Water Technologies Corp.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
26 May 2023, 16:24:46 UTC
Prior SEC filing
22 May 2023
Next SEC filing
15 Jun 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John DiMascio, Attorney-in-Fact for Ronald C. Keating

Key filing fact

Ronald C. Keating filed Form 4 for Evoqua Water Technologies Corp. on 26 May 2023.

Key facts

  • This page summarizes Ronald C. Keating's Form 4 filing for Evoqua Water Technologies Corp..
  • 8 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 26 May 2023, 16:24.

Change

  • Previous filing in this sequence was filed on 22 May 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQUA transaction

Common Stock

Award

Transaction value
$0
Shares
+249,362
Change %
+30%
Price
$0.000000
Shares after
1,093,399
Date
24 May 2023
Ownership
Direct
Footnotes
F1
AQUA transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-1,093,399
Change %
-100%
Price
Shares after
0
Date
24 May 2023
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQUA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-1,000,000
Change %
-100%
Price
Shares after
0
Date
24 May 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,000,000
Exercise price
$4.64
Footnotes
F3, F4, F5
AQUA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-29,653
Change %
-100%
Price
Shares after
0
Date
24 May 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
29,653
Exercise price
$7.42
Footnotes
F3, F4, F5
AQUA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-294,864
Change %
-100%
Price
Shares after
0
Date
24 May 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
294,864
Exercise price
$20.88
Footnotes
F3, F4, F5
AQUA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-304,935
Change %
-100%
Price
Shares after
0
Date
24 May 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
304,935
Exercise price
$12.67
Footnotes
F3, F4, F5
AQUA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-252,684
Change %
-100%
Price
Shares after
0
Date
24 May 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
252,684
Exercise price
$23.63
Footnotes
F4, F5, F6
AQUA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-192,693
Change %
-100%
Price
Shares after
0
Date
24 May 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
192,693
Exercise price
$24.76
Footnotes
F4, F5, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Ronald C. Keating is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 7 footnotes

Footnote F1

Represents performance share units ("PSUs") that became earned (at target award level) pursuant to the merger agreement among Xylem Inc., Fore Merger Sub, Inc. and the issuer, dated as of Jan. 22, 2023, upon effectiveness of the merger on May 24, 2023.

Footnote F2

Disposed of pursuant to the merger agreement. Upon effectiveness of the merger, (i) each issued and outstanding share of issuer common stock was exchanged for 0.48 Xylem common shares, with cash paid in lieu of fractional shares, and (ii) unvested restricted stock units ("RSUs") and PSUs (at target award level) were converted into RSUs relating to Xylem common shares, by multiplying the number of shares of issuer common stock underlying the award and 0.48, rounded down to the nearest whole share.

Footnote F3

This option is fully vested.

Footnote F4

Pursuant to the merger agreement, outstanding options for issuer common stock were assumed by Xylem and converted into options for Xylem common shares, in an amount equal to the number of shares of issuer common stock underlying the options multiplied by 0.48, rounded down to the nearest whole share.

Footnote F5

Pursuant to the merger agreement, the Xylem option exercise price is equal to the issuer option exercise price divided by 0.48, rounded up to the nearest whole cent.

Footnote F6

This option vests in four equal annual installments starting on Jan. 1, 2021.

Footnote F7

This option vests in four equal annual installments starting on Feb. 16, 2022.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .